Browse SART3

Summary
SymbolSART3
Namesquamous cell carcinoma antigen recognized by T cells 3
Aliases KIAA0156; RP11-13G14; TIP110; squamous cell carcinoma antigen recognised by T cells 3; DSAP1; p110(nrb); SAR ......
Chromosomal Location12q24.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus, nucleoplasm Nucleus, Cajal body Nucleus speckle Cytoplasm
Domain PF05391 Lsm interaction motif
PF00076 RNA recognition motif. (a.k.a. RRM
Function

U6 snRNP-binding protein that functions as a recycling factor of the splicing machinery. Promotes the initial reassembly of U4 and U6 snRNPs following their ejection from the spliceosome during its maturation (PubMed:12032085). Also binds U6atac snRNPs and may function as a recycling factor for U4atac/U6atac spliceosomal snRNP, an initial step in the assembly of U12-type spliceosomal complex. The U12-type spliceosomal complex plays a role in the splicing of introns with non-canonical splice sites (PubMed:14749385). May also function as a substrate-targeting factor for deubiquitinases like USP4 and USP15. Recruits USP4 to ubiquitinated PRPF3 within the U4/U5/U6 tri-snRNP complex, promoting PRPF3 deubiquitination and thereby regulating the spliceosome U4/U5/U6 tri-snRNP spliceosomal complex disassembly (PubMed:20595234). May also recruit the deubiquitinase USP15 to histone H2B and mediate histone deubiquitination, thereby regulating gene expression and/or DNA repair (PubMed:24526689). May play a role in hematopoiesis probably through transcription regulation of specific genes including MYC (By similarity). ; FUNCTION: Regulates Tat transactivation activity through direct interaction. May be a cellular factor for HIV-1 gene expression and viral replication.

> Gene Ontology
 
Biological Process GO:0000244 spliceosomal tri-snRNP complex assembly
GO:0000245 spliceosomal complex assembly
GO:0000375 RNA splicing, via transesterification reactions
GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile
GO:0000387 spliceosomal snRNP assembly
GO:0000398 mRNA splicing, via spliceosome
GO:0006323 DNA packaging
GO:0006333 chromatin assembly or disassembly
GO:0006334 nucleosome assembly
GO:0006397 mRNA processing
GO:0008380 RNA splicing
GO:0016570 histone modification
GO:0016578 histone deubiquitination
GO:0016579 protein deubiquitination
GO:0022613 ribonucleoprotein complex biogenesis
GO:0022618 ribonucleoprotein complex assembly
GO:0031056 regulation of histone modification
GO:0031058 positive regulation of histone modification
GO:0031497 chromatin assembly
GO:0034728 nucleosome organization
GO:0045862 positive regulation of proteolysis
GO:0048872 homeostasis of number of cells
GO:0065004 protein-DNA complex assembly
GO:0070646 protein modification by small protein removal
GO:0071103 DNA conformation change
GO:0071425 hematopoietic stem cell proliferation
GO:0071824 protein-DNA complex subunit organization
GO:0071826 ribonucleoprotein complex subunit organization
GO:0072089 stem cell proliferation
GO:0090085 regulation of protein deubiquitination
GO:1902275 regulation of chromatin organization
GO:1903003 positive regulation of protein deubiquitination
GO:1903320 regulation of protein modification by small protein conjugation or removal
GO:1903322 positive regulation of protein modification by small protein conjugation or removal
GO:1903584 regulation of histone deubiquitination
GO:1903586 positive regulation of histone deubiquitination
GO:1905269 positive regulation of chromatin organization
Molecular Function GO:0002020 protease binding
GO:0017069 snRNA binding
GO:0017070 U6 snRNA binding
GO:0030621 U4 snRNA binding
GO:0030624 U6atac snRNA binding
GO:0042393 histone binding
GO:1990381 ubiquitin-specific protease binding
Cellular Component GO:0005691 U6atac snRNP
GO:0015030 Cajal body
GO:0016604 nuclear body
GO:0016607 nuclear speck
GO:0030532 small nuclear ribonucleoprotein complex
GO:0071001 U4/U6 snRNP
GO:0097525 spliceosomal snRNP complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolSART3
Namesquamous cell carcinoma antigen recognized by T cells 3
Aliases KIAA0156; RP11-13G14; TIP110; squamous cell carcinoma antigen recognised by T cells 3; DSAP1; p110(nrb); SAR ......
Chromosomal Location12q24.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SART3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SART3 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21480325Hepatocellular CarcinomaInhibit immunity (T/NK cell function); immunotherapy targetThe TAAs consisting of cyclophilin B, squamous cell carcinoma antigen recognized by T cells (SART) 2, SART3, p53, multidrug resistance-associated protein (MRP) 3, alpha-fetoprotein (AFP) and human telomerase reverse transcriptase (hTERT) were frequently recognized by T cells and these TAA-derived peptides were capable of generating peptide-specific CTLs in HCC patients, which suggested that these TAAs are immunogenic. Cyclophilin B, SART2, SART3, p53, MRP3, AFP, and hTERT were immunogenic targets for HCC immunotherapy.
Summary
SymbolSART3
Namesquamous cell carcinoma antigen recognized by T cells 3
Aliases KIAA0156; RP11-13G14; TIP110; squamous cell carcinoma antigen recognised by T cells 3; DSAP1; p110(nrb); SAR ......
Chromosomal Location12q24.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SART3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSART3
Namesquamous cell carcinoma antigen recognized by T cells 3
Aliases KIAA0156; RP11-13G14; TIP110; squamous cell carcinoma antigen recognised by T cells 3; DSAP1; p110(nrb); SAR ......
Chromosomal Location12q24.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SART3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0440.799
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1970.911
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0680.959
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3170.293
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2290.914
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4320.876
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0830.806
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0620.97
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1270.943
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5470.673
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8480.667
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1330.00398
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SART3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSART3
Namesquamous cell carcinoma antigen recognized by T cells 3
Aliases KIAA0156; RP11-13G14; TIP110; squamous cell carcinoma antigen recognised by T cells 3; DSAP1; p110(nrb); SAR ......
Chromosomal Location12q24.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SART3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSART3
Namesquamous cell carcinoma antigen recognized by T cells 3
Aliases KIAA0156; RP11-13G14; TIP110; squamous cell carcinoma antigen recognised by T cells 3; DSAP1; p110(nrb); SAR ......
Chromosomal Location12q24.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SART3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SART3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSART3
Namesquamous cell carcinoma antigen recognized by T cells 3
Aliases KIAA0156; RP11-13G14; TIP110; squamous cell carcinoma antigen recognised by T cells 3; DSAP1; p110(nrb); SAR ......
Chromosomal Location12q24.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SART3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSART3
Namesquamous cell carcinoma antigen recognized by T cells 3
Aliases KIAA0156; RP11-13G14; TIP110; squamous cell carcinoma antigen recognised by T cells 3; DSAP1; p110(nrb); SAR ......
Chromosomal Location12q24.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SART3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSART3
Namesquamous cell carcinoma antigen recognized by T cells 3
Aliases KIAA0156; RP11-13G14; TIP110; squamous cell carcinoma antigen recognised by T cells 3; DSAP1; p110(nrb); SAR ......
Chromosomal Location12q24.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SART3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSART3
Namesquamous cell carcinoma antigen recognized by T cells 3
Aliases KIAA0156; RP11-13G14; TIP110; squamous cell carcinoma antigen recognised by T cells 3; DSAP1; p110(nrb); SAR ......
Chromosomal Location12q24.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SART3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.